Literature DB >> 22871919

Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.

Franck Chenu1, Mostafa El Mansari, Pierre Blier.   

Abstract

Agomelatine is a melatonergic MT1/MT2 agonist and a serotonin (5-HT) 5-HT(2C) antagonist. The effects of 2-day and 14-day administration of agomelatine were investigated on the activity of ventral tegmental area (VTA) dopamine (DA), locus coeruleus (LC) norepinephrine (NE), and dorsal raphe nucleus (DRN) 5-HT neurons using in vivo electrophysiology in rats. The 5-HT(1A) transmission was assessed at hippocampus CA3 pyramidal neurons. After a 2-day regimen of agomelatine (40 mg/kg/day, i.p.), an increase in the number of spontaneously active VTA-DA neurons (p<0.001) and in the firing rate of LC-NE neurons (p<0.001) was observed. After 14 days, the administration of agomelatine induced an increase in: (1) the number of spontaneously active DA neurons (p<0.05), (2) the bursting activity of DA neurons (bursts/min, p<0.01 and percentage of spikes occurring in bursts, p<0.05), (3) the firing rate of DRN-5-HT neurons (p<0.05), and (4) the tonic activation of postsynaptic 5-HT(1A) receptors located in the hippocampus. The increase in 5-HT firing rate was D2 dependent, as it was antagonized by the D2 receptor antagonist paliperidone. The enhancement of NE firing was restored by the 5-HT(2A) receptor antagonist MDL-100,907 after the 14-day regimen. All the effects of agomelatine were antagonized by a single administration of the melatonergic antagonist S22153 (except for the increase in the percentage of spikes occurring in burst for DA neurons). The present results suggest that (1) agomelatine exerts direct (2 days) and indirect (14 days) modulations of monoaminergic neuronal activity and (2) the melatonergic agonistic activity of agomelatine contributes to the enhancement of DA and 5-HT neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871919      PMCID: PMC3527117          DOI: 10.1038/npp.2012.140

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  45 in total

1.  Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.

Authors:  Yoshimoto Sekine; Katsuaki Suzuki; P Veeraraghavan Ramachandran; Thomas P Blackburn; Charles R Ashby
Journal:  Synapse       Date:  2007-02       Impact factor: 2.562

2.  Use of slow-release melatonin in treatment-resistant depression.

Authors:  E J Dalton; D Rotondi; R D Levitan; S H Kennedy; G M Brown
Journal:  J Psychiatry Neurosci       Date:  2000-01       Impact factor: 6.186

3.  Desensitization of the neuronal 5-HT carrier following its long-term blockade.

Authors:  G Piñeyro; P Blier; T Dennis; C de Montigny
Journal:  J Neurosci       Date:  1994-05       Impact factor: 6.167

4.  Chronic melatonin treatment and its precursor L-tryptophan improve the monoaminergic neurotransmission and related behavior in the aged rat brain.

Authors:  Susana Esteban; Celia Garau; Sara Aparicio; David Moranta; Pere Barceló; Maria Antonia Fiol; Rubén Rial
Journal:  J Pineal Res       Date:  2010-01-17       Impact factor: 13.007

5.  Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area.

Authors:  Eliyahu Dremencov; Mostafa El Mansari; Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2009-05       Impact factor: 6.186

6.  Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.

Authors:  Thomas P Blackburn; Yoshio Minabe; Derek N Middlemiss; Yukihiko Shirayama; Kenji Hashimoto; Charles R Ashby
Journal:  Synapse       Date:  2002-12-01       Impact factor: 2.562

7.  Melatonin for the treatment of sleep disturbances in major depressive disorder.

Authors:  O T Dolberg; S Hirschmann; L Grunhaus
Journal:  Am J Psychiatry       Date:  1998-08       Impact factor: 18.112

8.  Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.

Authors:  Eliyahu Dremencov; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2007-05-27       Impact factor: 4.530

Review 9.  Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.

Authors:  Giorgio Racagni; Marco Andrea Riva; Raffaella Molteni; Laura Musazzi; Francesca Calabrese; Maurizio Popoli; Daniela Tardito
Journal:  World J Biol Psychiatry       Date:  2011-10-14       Impact factor: 4.132

10.  Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Authors:  Anthony Hale; Ricardo-Marcelo Corral; Claudio Mencacci; Jeronimo Saiz Ruiz; Cristina Albarran Severo; Valentim Gentil
Journal:  Int Clin Psychopharmacol       Date:  2010-11       Impact factor: 1.659

View more
  21 in total

Review 1.  Mood-related central and peripheral clocks.

Authors:  Kyle D Ketchesin; Darius Becker-Krail; Colleen A McClung
Journal:  Eur J Neurosci       Date:  2018-11-29       Impact factor: 3.386

Review 2.  Dopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults.

Authors:  Stephanie M Matt; Peter J Gaskill
Journal:  Brain Res       Date:  2019-08-21       Impact factor: 3.252

Review 3.  Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression.

Authors:  Marcela Valdés-Tovar; Rosa Estrada-Reyes; Héctor Solís-Chagoyán; Jesús Argueta; Ana María Dorantes-Barrón; Daniel Quero-Chávez; Ricardo Cruz-Garduño; Montserrat G Cercós; Citlali Trueta; Julián Oikawa-Sala; Margarita L Dubocovich; Gloria Benítez-King
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

Review 4.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 5.  How might circadian rhythms control mood? Let me count the ways...

Authors:  Colleen A McClung
Journal:  Biol Psychiatry       Date:  2013-04-01       Impact factor: 13.382

6.  Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat.

Authors:  Inge Oberholzer; Marisa Möller; Brendan Holland; Olivia M Dean; Michael Berk; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2017-11-03       Impact factor: 3.584

7.  Psychological Impact of Shift Work.

Authors:  Philip Cheng; Christopher L Drake
Journal:  Curr Sleep Med Rep       Date:  2018-04-12

8.  Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.

Authors:  Valentina Vengeliene; Hamid R Noori; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2015-05-21       Impact factor: 7.853

Review 9.  Agomelatine: an agent against anhedonia and abulia?

Authors:  J Thome; P Foley
Journal:  J Neural Transm (Vienna)       Date:  2013-12-06       Impact factor: 3.575

Review 10.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.